<DOC>
	<DOCNO>NCT00578708</DOCNO>
	<brief_summary>The purpose feasibility study investigate safety AMPLATZER® Membranous VSD Occluder treatment hemodynamically significant Perimembranous Ventricular Septal Defects .</brief_summary>
	<brief_title>Closure Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER</brief_title>
	<detailed_description />
	<mesh_term>Heart Septal Defects</mesh_term>
	<mesh_term>Heart Septal Defects , Ventricular</mesh_term>
	<criteria>Patients hemodynamically significant Perimembranous ventricular septal defect Patients &lt; 8 kg Supracristal ventricular septal defect Left ventricle right atrium shunt Prolapse aortic valve Right leave shunt defect Perimembranous VSD aneurysm multiple shunt successfully close one device Patients &lt; 2mm aortic rim Sepsis ( local/generalized ) Complex heart lesion atrioventricular canal defect Tetralogy Fallot . Patients ASA intolerant Unable follow duration clinical trial Inability obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>membranous</keyword>
	<keyword>ventricular</keyword>
	<keyword>septal</keyword>
	<keyword>defect</keyword>
	<keyword>VSD</keyword>
</DOC>